Table 2. MHC alleles observed within the abacavir-hypersensitive and -tolerant controls.
| MHC marker | Hypersensitive, n (%) | Tolerant, n (%) | OR | Positive predictive value, % | Negative predictive value, % |
|---|---|---|---|---|---|
| HLA-B*5701 | 17 (94.4) | 4 (1.7) | 960.0 | 78.9 | 99.4 |
| C4A6 | 14 (77.8) | 7 (3.0) | 111.5 | 72.2 | 98.3 |
| HLA-DRB1*0701, HLA-DQ3 | 14 (77.8) | 11 (4.8) | 69.7 | 65.0 | 98.3 |
| Hsp70-Hom M493T | 17 (94.4) | 51 (22.2) | 59.7 | 25.4 | 99.3 |
| HLA-B*5701, C4A6 | 14 (77.8) | 0 | 1,485.0 | 100.0 | 98.4 |
| HLA-B*5701, HLA-DRB1*0701, HLA-DQ3 | 14 (77.8) | 0 | 1,485.0 | 100.0 | 98.4 |
| HLA-B*5701 Hsp70-Hom M493T | 17 (94.4) | 1 (0.43) | 3,893.0 | 93.8 | 99.5 |
The HLA-B*5701, HLA-DRB1*0701, HLA-DQ3, and C4A6 typing was performed as described in our previous study (1). The Hsp70-Hom M493T SNPs were typed by using a combination of restriction fragment-length polymorphism and sequence-specific primer polymorphism assays. For all MHC markers, corrected P values are <0.00001. Positive and negative predictive values were calculated within the retrospective abacavir-exposed cohort (n = 200), to exclude potential confounding caused by the active exclusion of abacavir use among those carrying 57.1 AH markers in the prospective cohort.